Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other financing activities (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Other financing activities for 3 consecutive years, with $8.6 million as the latest value for Q3 2025.

  • Quarterly Other financing activities rose 431800.0% to $8.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 million through Dec 2025, up 1490.79% year-over-year, with the annual reading at $8.6 million for FY2025, 1490.79% up from the prior year.
  • Other financing activities hit $8.6 million in Q3 2025 for Compass Therapeutics, up from $815000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $8.6 million in Q3 2025 to a low of -$815000.0 in Q1 2025.
  • Historically, Other financing activities has averaged $1.1 million across 3 years, with a median of $500.0 in 2023.
  • Biggest YoY gain for Other financing activities was 431800.0% in 2025; the steepest drop was 499.26% in 2025.
  • Year by year, Other financing activities stood at -$1000.0 in 2023, then tumbled by 100.0% to -$2000.0 in 2024, then soared by 432000.0% to $8.6 million in 2025.
  • Business Quant data shows Other financing activities for CMPX at $8.6 million in Q3 2025, $815000.0 in Q2 2025, and -$815000.0 in Q1 2025.